The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...
Exclusive ex-China rights extend to up to 10 partnered biosimilar programs, positioning Sandoz to shape development and registration strategy using early commercial and market-access input. Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results